Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.51 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749486 | 0.80 | CRHR1 (0.48) | CRHR1RUNX1ALPLSCN9A | |
| SCHEMBL6081651 | 0.78 | CRHR1 (0.47) | CRHR1RUNX1ALPLSCN9ACYP1A2 | |
| SCHEMBL5804119 | 0.77 | CRHR1 (0.46) | CRHR1RUNX1ALPLSCN9ACYP1A2 | |
| SCHEMBL6344985 | 0.76 | CRHR1 (0.47) | CRHR1RUNX1ALPLSCN9A | |
| SCHEMBL4884766 | 0.76 | CRHR1 (0.51) | CRHR1RUNX1SCN9ACYP1A2 | |
| SCHEMBL5431714 | 0.73 | CRHR1 (0.69) | CRHR1RUNX1SCN9A | |
| SCHEMBL5783224 | 0.73 | CRHR1 (0.43) | CRHR1SCN9ACYP1A2 | |
| SCHEMBL5420406 | 0.71 | CRHR1 (0.68) | CRHR1RUNX1SCN9A | |
| SCHEMBL4884652 | 0.71 | CRHR1 (0.46) | CRHR1RUNX1SCN9ACYP1A2 | |
| SCHEMBL6081645 | 0.70 | CRHR1 (0.41) | CRHR1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1680424-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | Neurogen Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005023806-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199823-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CRHR1 1/4885RUNX1 1387/4885ALPL 4598/4885 |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | CRHR1, CRHR2, HTR5A | CRHR1 1/4885RUNX1 1387/4885ALPL 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.